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Abstract Pokeweed antiviral protein (PAP), a ribosome-
inactivating protein isolated from the leaves of Phytolacca
americana, reveals potent antiviral activity against viruses or
cytotoxic action against cells once inside the cytoplasm. There-
fore PAP is a good candidate to be used as an immunotoxin. We
constructed a bacterial expression plasmid encoding PAP as a
fusion protein with gonadotropin-releasing hormone (GnRH), a
neuropeptide with receptor sites on several gynaecologic tumors.
The resulting recombinant toxin was produced in Escherichia coli
and accumulated in inclusion bodies. After purification under
denaturing conditions, renaturated GnRH-PAP shows an IC50 of
3 nM on in vitro translation assays and selectively inhibits the
growth of the GnRH receptor positive Ishikawa cell line (ID50 of
15 nM); on the other hand, neither GnRH nor PAP alone had
any effect.
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1. Introduction
Immunotoxins and recombinant toxins are cytotoxic agents
designed to selectively kill populations of cells that display
speci¢c cell surface antigens. These toxins are developed
mainly for cancer therapy [1]. They are also employed for
the treatment of other diseases such as acquired immunode¢-
ciency syndrome (AIDS) [2] and are useful as tools in neuro-
biology [3]. They are composed of a targeting moiety (anti-
body, growth factor or hormone) linked to a bacterial or a
plant toxin (Pseudomonas exotoxin, diphteria toxin or ribo-
some-inactivating proteins e.g. ricin or pokeweed antiviral
protein) by chemical coupling or recombinant DNA technol-
ogy [4^7].
Pokeweed antiviral protein (PAP) is a ribosome-inactivating
protein produced by the plant Phytolacca americana [8]. This
enzyme is an RNA N-glycosidase which speci¢cally removes
an adenine residue from a highly conserved loop in the large
ribosomal RNA of eukaryotic and prokaryotic ribosomes
[9,10], inducing a conformational change in the subunit.
This prevents the binding of the elongation factor EF2, thus
blocking protein synthesis. PAP has been classi¢ed as an anti-
viral agent because it reduces the infectivity of many plant
viruses when co-inoculated with a virus on the leaves of sus-
ceptible species [11,12]. Ready et al. have shown that PAP is
sequestered in the cell wall matrix and have proposed a model
for the mechanism of its antiviral activity [13]. Their hypoth-
esis has been corroborated with the demonstration of PAP
having activity against pokeweed ribosomes [14]. Thus, PAP
could be released in the cytoplasm of infected cells, together
with the virus, and exert its toxic activity on the ribosomes.
Virus replication would be thereby prevented by a local sui-
cide. The transport pathway of this powerful toxin (IC50 of
1 nM on pokeweed ribosomes) synthesized at a very high yield
(up to 0.5% of soluble leaf proteins) [14] has not been yet
elucidated. Our group has recently identi¢ed an inactive com-
plex form of PAP called PAPi [15]. Although the composition
of PAPi is still under investigation, hypothetically PAPi may
be a self-protection mechanism of pokeweed cells against PAP
which might be misaddressed during its biosynthesis. The
amount of PAP versus complexed PAP (in PAPi) can be esti-
mated in a plant extract with an ELISA which discriminates
between the two forms [16]. PAP has also been shown to be
highly toxic in vitro to cells infected with di¡erent animal
viruses including the human immunode¢ciency virus (HIV)
[17^19]. Unlike type II ribosome-inactivating proteins (RIPs,
e.g. ricin) or bacterial toxins (which are able to penetrate
living cells through their cell recognition domain), PAP is
not cytotoxic. This protein, which contains four cysteine res-
idues involved in two intramolecular disul¢de bonds, is not
glycosylated. Consequently, PAP represents an excellent can-
didate for the toxic moiety of an immunotoxin. It has already
been chemically conjugated to di¡erent antibodies. It has been
used in a preclinical study for treatment of B lineage leuke-
mia/lymphoma [20], against HIV-infected, CD4-positive cells
[21] and as a purging agent in the case of human autologous
bone marrow transplantation [22]. More recently, Dore et al.
have produced in Escherichia coli a recombinant hybrid toxin
which combines the interleukin 2 (IL2) with a mutant form of
PAP. This mutant form, enzymatically active against eukary-
otic ribosomes, allowed E. coli growth [23].
The gonadotropin-releasing hormone (GnRH), also called
luteinizing hormone-releasing hormone (LH-RH), is a neuro-
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decapeptide. After binding to its receptor on pituitary cells, it
triggers the secretion of the luteinizing hormone (LH) and
follicle stimulating hormone (FSH). These gonadotropin hor-
mones control the activity of the gonads. A growing interest
has developed for the application of GnRH and related pep-
tides in the ¢elds of gynaecology and oncology. GnRH and its
analogues have been used in treatment of hypogonadism and
infertility. It is also used in medical castration for the treat-
ment of gonadotropin dependent cancers [24].
Moreover, GnRH receptors have been identi¢ed on tumor
cells from mammary, endometrial, prostatic and pancreatic
tissues as well as on tumor cell lines [25^28].
For these reasons, GnRH is a very good candidate for the
engineering of recombinant chimeric toxins. Furthermore, this
peptide binds to its receptor with high a⁄nity (Kd about 1039
M) [29] and is not immunogenic.
In this paper, we report the elaboration of a chimeric toxin
associating PAP and the GnRH by recombinant gene tech-
nology; this recombinant protein is toxic towards the endo-
metrial cancer cell line Ishikawa harboring the GnRH recep-
tor.
2. Materials and methods
2.1. GnRH-PAP construction and expression
The cDNA encoding the recombinant PAP was cloned in the ex-
pression vector pOPE90 as previously described [30]. The GnRH-PAP
fusion cDNA was ampli¢ed by PCR. The sense DNA primer (5P-CAg
gat ccC AGC ACT GGT CCT ATG GAC TGC GCC CTG GAG CCA
AGA AAC TGA ACG ACG CTC AGG CGC CGA AGA GTG ATA
TGG TGA ATA CAA TCA TCA TCT AC-3P) introduced a BamHI
restriction site to facilitate the cloning (lower case), the full sequence
of GnRH (bold), followed by the staphylococcal protein A FB frag-
ment sequence (italic) and a sequence encoding the eight ¢rst amino
acids of mature PAP (upper cases) [31,32]. The FB fragment sequence
corresponded to the residues 48^60 of the fragment B of the staph-
ylococcal protein A (FB) and served as a linker to improve the e⁄-
ciency and the solubility of the fusion protein [31]. The full length
cDNA of PAP except for the 22 codons, corresponding to N-terminal
signal peptide, served as a template for PCR ampli¢cation.
The antisense primer (5P-CGC gga tcc GAA TCC TTC AAA TAG
AT-3P) was designed to introduce a BamHI restriction site (lower
case) at the 3P-end of the PAP gene. The PCR-ampli¢ed sequence
was extracted from agarose gel using the ‘Cleanmix’ kit (Talent,
Italy). After digestion with BamHI, it was ligated to BamHI site of
the pQE60 expression vector (Qiagen) to make the pQE60/GnRH-
PAP construction (Fig. 1). These ligation products were used to trans-
form rubidium chloride competent JM 109 bacterial cells. The re-
combinant plasmid was puri¢ed from LB culture medium containing
ampicillin (50 Wg/ml) and sequenced. Then, it was employed to trans-
form rubidium chloride competent M15 bacterial cells containing the
pREP4 plasmid. Bacterial growth was performed with overnight cul-
ture in LB medium containing ampicillin (50 Wg/ml) and kanamycin
(25 Wg/ml). Once the LB culture medium absorbance reached 0.5 at
600 nm, the GnRH-PAP fusion protein expression was induced by the
addition of 1 mM IPTG for 2 h at 37‡C.
2.2. Puri¢cation of the GnRH-PAP recombinant toxin
After centrifugation (2000Ug, 5 min, 4‡C), the bacterial pellet was
suspended in bu¡er A (50 mM Tris^HCl, pH 8, 100 mM NaCl, 1 mM
EDTA, 0.2 mM L-mercaptoethanol, 0.05% Tween 20) 5 ml/g of wet
weight, sonicated (10 bursts at 4‡C) and centrifuged (8000Ug, 10 min,
4‡C). The supernatant was discarded. The inclusion bodies were sus-
pended in bu¡er B (8 M urea, 0.1 M sodium phosphate, 0.2 mM L-
mercaptoethanol, 0.01 M Tris^HCl, pH 8) sonicated for 1 min and
incubated in the bu¡er for 1 h at room temperature under gentle
shaking. The solution was cleared by another centrifugation
(10 000Ug, 10 min, room temperature) and was applied on a Ni-
NTA column (1 cmU10 cm, Qiagen) equilibrated with bu¡er B at a
£ow rate of 0.1 ml per hour. Proteins bound to the column by non-
speci¢c interactions were removed with bu¡er C (8 M urea, 0.1 M
sodium phosphate, 0.01 M Tris, pH 6.3, 0.2 mM L-mercaptoethanol,
imidazole 10 mM) and the chimeric protein was eluted from the col-
umn with bu¡er C in the presence of 250 mM imidazole. The puri¢ed
protein was detected in the elution fractions by SDS^PAGE. For the
refolding, the GnRH-PAP containing fractions were pooled, diluted 5
times and dialyzed 3 times against 5 l of 50 mM Tris^HCl, pH 7.5,
100 mM NaCl, 0.1 mM EDTA, 0.2 mM L-mercaptoethanol at room
temperature for 48 h. The total protein content was estimated by the
method of Lowry [33].
2.3. Western blotting analyses and immunoprecipitation
The proteins were treated under denaturing conditions (sample
bu¡er: 62.5 mM Tris^HCl, pH 6.8, 2% SDS (w/v), 10% glycerol (v/
v), 5% L-mercaptoethanol (v/v), 0.02% bromophenol blue (w/v)) and
separated by SDS^PAGE according to Laemmli [34]. The gels were
stained with Coomassie R250 blue dye. For Western blotting analysis,
the proteins were transferred from the gel onto PVDF membrane
using a Bio-Rad trans-blot apparatus as described by Towbin [35].
After 1 h blocking in PBS^BSA bu¡er (10 mM sodium phosphate, pH
7.4, 150 mM NaCl, 1% of BSA) at room temperature, the membrane
was incubated for 2 h with the culture supernatant containing anti-
PAP monoclonal antibodies [36]. After washing with PBS bu¡er, con-
taining 0.05% Tween 20 and 0.5 M NaCl, the membrane was incu-
bated for 30 min with alkaline phosphatase conjugated goat anti-
mouse antibodies (Biosys, France) which was diluted 1/2000 in
PBS^BSA bu¡er. After extensive washing, immunoreactive bands
were visualized with a substrate solution containing nitroblue tetrazo-
lium chloride (NBT, 0.33 mg/ml) and 5-bromo-1-chloro-3-indolyl
phosphate (BCIP, 0.165 mg/ml, Promega) in 0.1 M Tris^HCl bu¡er,
pH 9.5 containing 0.1 M NaCl and 5 mM MgCl2.
Puri¢ed recombinant GnRH-PAP (5 Wg) was immunoprecipitated
either with 3 Wg of polyclonal anti-GnRH (a generous gift from Prof.
D. Fellmann, UPRESA CNRS 6025 Besanc°on, France) or with poly-
clonal anti-PAP antibodies in Tris bu¡er 100 mM pH 7.4 (¢nal
volume 100 Wl). Forty microliters of protein A Sepharose (Sigma)
equilibrated in the same bu¡er were added and the mixture incubated
for 1 h at room temperature under gentle agitation. The protein A
Sepharose was recovered by centrifugation (12 000Ug 15 min, room
temperature) and washed twice with PBS containing 0.5 M NaCl. The
immunoprecipitated proteins were removed from protein A with
SDS^PAGE sample bu¡er and analyzed by Western blotting using
monoclonal anti-PAP antibodies for the detection.
2.4. Inhibition of in vitro translation
Di¡erent concentrations of GnRH-PAP or PAP alone (2 Wl) were
added to the translation mixture. The latter contained 4 Wl of rabbit
reticulocyte lysate (Promega), 0.2 Wl of a mixture of di¡erent amino
acids (minus methionine) at a concentration of 1 mM, 0.2 Wl of
L-[35S]methionine (3U108 Bq/ml, Dupont) and 5.2 Wl of H2O. The
reaction was started by the addition of 0.2 Wl of a stock solution of
brome mosaic virus (BMV) RNA at 0.5 mg/ml. After incubation (1 h
at 30‡C), 2 Wl aliquots of each assay were analyzed by SDS^PAGE.
Finally, the gel was autoradiographed. Densitometric analyses of the
band of 35 kDa encoded by BMV RNA was performed with the Bio-
Rad ‘Gel-Doc’ System.
2.5. Detection of GnRH receptor expression on cell lines
Expression of the GnRH receptor was checked on various cell lines
by RT-PCR and Western blotting.
To perform RT-PCR analyses, total RNAs from rat pituitaries (a
generous gift from Professor D. Fellmann, UPRESA CNRS 6025
Besanc°on, France) and from cultured cell lines were extracted by
the guanidium isothiocyanate method according to Chomczinski
and Sacchi [37]. Complementary DNA was synthesized with a Molo-
ney murine leukemia virus reverse transcriptase (Life Technologies).
The reaction mixture (25 Wl) contained 5 Wg of total RNA, 10 WM of
oligo-dT primer, 1URT bu¡er, a mixture of each dNTP 0.5 mM and
0.5 units of enzyme; it was incubated for 1 h at 37‡C. PCR and nested
PCR were performed on the cDNA with two sets of primers as de-
scribed by Ima|« et al. [28].
For Western blotting analyses, cellular membrane enriched frac-
tions prepared according to Wiznizer et al. [38] were separated by
SDS^PAGE, transferred onto PVDF membranes and revealed with
an anti-GnRH receptor antibody (Santa-Cruz).
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2.6. Cytotoxicity
Ishikawa cells were a generous gift from Dr L. Bermont (IETG).
The human breast cancer cell line MCF-7 was kindly provided by Dr
S. Saez (Centre hospitalier Lyon Sud France). The cells were main-
tained in Dulbecco’s modi¢ed medium (Sigma) supplemented with
penicillin, 100 U/ml, streptomycin, 100 Wg/ml, amphotericin B, 0.25
Wg/ml penicillin (Sigma) and 10% fetal calf serum. All cell lines were
cultured in a humidi¢ed atmosphere with 5% CO2 at 37‡C and the
medium was replaced every 2^3 days.
For cytotoxicity assays, the cells were seeded in 96-microwell plates
(4000 cells/well) in the same medium to which various concentrations
of GnRH-PAP were added. After 36 h of incubation, viability assay
was performed by using the cell proliferation kit II (XTT) (Roche
Diagnostics).
3. Results
3.1. Expression and puri¢cation of recombinant GnRH-PAP
After induction of M15 E. coli cells, the recombinant
GnRH-PAP, mainly contained in inclusion bodies, was puri-
¢ed to homogeneity by Ni2-NTA-chelate a⁄nity chromatog-
raphy at a yield of 1 mg/l of bacterial culture and identi¢ed as
a 36 kDa protein by SDS^PAGE (Fig. 2A). Western blotting
analyses allowed us to detect PAP moiety in the puri¢ed frac-
tion at the same molecular weight as that of the stained pu-
ri¢ed protein (Fig. 2B). Immunoprecipitation analyses allowed
the detection of the GnRH moiety in the GnRH-PAP fusion
protein (Fig. 2C), thus con¢rming the presence of both the
entities in the fusion product.
3.2. Analyses of in vitro toxicity of GnRH-PAP
As PAP inhibits in vitro protein synthesis, we tested if
GnRH-PAP has a similar inhibitory activity. Fig. 3 shows
that GnRH-PAP was able to inhibit protein synthesis in a
dose dependent manner with an IC50 of 3 nM. A control
assay indicated that puri¢ed PAP shows an IC50 of 0.5 nM
(Fig. 3).
3.3. Detection of GnRH receptor in Ishikawa and MCF-7 cell
lines
Prior to cytotoxicity analyses, GnRH receptor expression
was checked both by RT-PCR and Western blotting analyses.
From Ishikawa cell RNAs, RT-PCR experiments allowed us
to amplify a 319 bp fragment similar to the one obtained with
the control RNAs from pituitary extracts (Fig. 4). No such
band was obtained from our MCF-7 cell line, although the
histone H3.3 347 bp fragment was correctly ampli¢ed (Fig. 4)
[39].
Western blotting analyses performed with a monoclonal
antibody against the GnRH receptor con¢rmed the RT-
PCR results : the GnRH receptor could only be detected in
Ishikawa cell extract (data not shown). Moreover, immuno-
£uorescence labelling experiments using FITC labelled GnRH
indicated a relatively heterogeneous labelling on Ishikawa
cells and no labelling on MCF-7 cells (data not shown).
3.4. Cytotoxicity of the GnRH-PAP fusion protein against
cultured cells
The puri¢ed GnRH-PAP chimeric toxin was incubated with
Fig. 1. Cloning strategy of the GnRH-PAP construct into the
pQE60 expression vector. PL, pectate lyase leader sequence; P/O,
promoter/operator sequence.
Fig. 2. Analysis of the GnRH-PAP puri¢ed protein. A: Detection
of the GnRH-PAP fusion toxin after Ni2-NTA-chelate a⁄nity
chromatography. Ten microliters of puri¢ed fraction were loaded on
a 12% denaturating polyacrylamide gel. The proteins were then
stained with Coomassie brilliant blue. B: Western blotting analyses
performed on the same puri¢ed fraction. The recombinant protein
was revealed with anti-PAP and PAL conjugated anti-mouse mono-
clonal antibodies (Biosys, dilution 1/4000). C: Immunoprecipitation
of the GnRH-PAP. GnRH was incubated with antibodies, immuno-
complexes were then adsorbed on protein A Sepharose, run on
SDS^PAGE and transferred as previously described. Immunological
detection was performed with anti-PAP monoclonal antibodies.
Lane 1, GnRH-PAP immunoprecipitated (IP) with no antibodies;
lane 2, GnRH-PAP IP by anti-PAP antibodies; lane 3, PAP IP by
anti-PAP antibodies; lane 4, GnRH-PAP IP by anti-GnRH anti-
bodies; lane 5, PAP IP with no antibodies.
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Ishikawa and MCF-7 cells in complete medium at concentra-
tions ranging from 5U1038 M to 10312 M. Fig. 5 shows that
GnRH-PAP was able to induce cell death of the Ishikawa cell
line, whereas GnRH alone or PAP alone did not decrease the
cell viability. The ID50 of GnRH-PAP was estimated to be 15
nM. MCF-7 cell cultures were not a¡ected by equivalent con-
centrations of GnRH-PAP (Fig. 6). Control of GnRH-PAP
speci¢city against Ishikawa cells was performed by incubating
together GnRH-PAP (1036 M) with free GnRH (1035 M).
The cell viability with GnRH-PAP was less than 10% of un-
treated control. Upon adding GnRH, it climbed up to 87%.
This result argues in favor of the speci¢city of the GnRH-PAP
fusion toxin.
4. Discussion
We have previously cloned and produced in high yields the
PAP cDNA in E. coli. This allowed us to produce recombi-
nant chimeric toxins combining PAP and cell binding ligands.
In this paper, we report the cloning and the expression of a
GnRH-PAP fusion construct. The cloning strategy was facili-
tated by the small size of the GnRH peptide (10 amino acids),
thus permitting us to directly insert the GnRH sequence at the
5P-extremity of the PAP cDNA. The choice of the 5P-extremity
of the PAP cDNA was dictated by the known importance of
the C-terminal extremity for PAP cytotoxicity [16,40]. The
resulting recombinant toxin GnRH-PAP was expressed and
easily puri¢ed to homogeneity by a one step NI2 a⁄nity
chromatography.
The presence of both PAP and GnRH moieties in the pu-
ri¢ed protein was asserted by two di¡erent techniques. PAP
was easily detected by Western blotting analyses, whereas
GnRH necessitated immunoprecipitation. In fact, the poly-
clonal anti-GnRH antibody provided by Professor Fellmann
was not able to detect the GnRH with Western blotting anal-
yses (D. Fellmann, personal communication). Thus, the pres-
ence of the GnRH moiety in the fusion protein was con¢rmed
by immunoprecipitation experiments.
The chimeric toxin was able to inhibit in vitro protein syn-
thesis with a relatively good e⁄ciency but to a lesser extent
than the puri¢ed native PAP or the recombinant PAP [30,41].
This slightly reduced activity could be due to a conformation-
al change possibly due to the presence of the GnRH moiety in
the N-terminus of the fusion product.
Prior to cytotoxicity experiments, the expression of the
GnRH receptor was tested by RT-PCR and Western blotting
analyses. We used a nested PCR in order to allow the detec-
tion of very low amounts of GnRH receptor messenger RNA.
Moreover, these primers [28] allowed the ampli¢cation of a
short sequence of the GnRH receptor cDNA. The same frag-
Fig. 3. Inhibition of in vitro translation. Rabbit reticulocyte lysates
5 Wl were incubated with BMV RNA as template, [35S]methionine, a
mixture of amino acids and various concentrations of either GnRH-
PAP or PAP. Then, 2 Wl aliquots were run in a 12% SDS^PAGE
and autoradiographed. In vitro translation rate was estimated from
gel scans done with a phosphorimager (Bio-Rad).
Fig. 4. Detection of gonadotropin-releasing hormone (GnRH) recep-
tor mRNA in di¡erent cell lines. Following reverse transcription,
the ¢rst-strand cDNA was ampli¢ed by polymerase chain reaction
(PCR) using a set of oligonucleotide primers speci¢c for the GnRH
receptor mRNA. A second PCR was performed on the ampli¢ed
DNA with internal primers yielding a 319 bp fragment (R, GnRH
receptor). As a control, ampli¢cation of the histone H3.3 cDNA
yielded a 347 bp fragment (H, histone). The cDNA was resolved on
a 2% agarose gel.
Fig. 5. GnRH-PAP toxic activity against cultured cells. Ishikawa
cells were seeded in 96-microwell plates and maintained in complete
medium at 37‡C for 2 days. Then, various concentrations of either
GnRH-PAP, GnRH or PAP were added. After 36 h of incubation,
cell viability was estimated with the cell proliferation kit II (XTT)
(Roche Diagnostics). Dot represents an average value (% of viability
of the control) of eight replicates.
Fig. 6. E¡ects of GnRH-PAP on Ishikawa and MCF-7 cell lines.
MCF-7 cells were seeded as described for Ishikawa cells and then
incubated with equivalent concentration of GnRH-PAP. Viability
tests were performed as previously described. Values represent an
average of eight replicates.
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ment could not be ampli¢ed from genomic DNA because of
the presence of two introns (respectively 4353 bp and 4972 bp
between the primers used for the ¢rst PCR cycle) [42]. Thus
unspeci¢c ampli¢ed products which would be provoked by
DNA contamination were prevented. The GnRH receptor
transcripts and protein were detected in the Ishikawa cell
line as well as in the pituitary control; surprisingly they
were absent in the MCF-7 cell line. The expression of the
GnRH receptor has been previously reported in the two cell
lines [25,26], however Chatzaki et al. failed to detect GnRH
receptor in the Ishikawa cell line [43]. The lack of expression
of the GnRH receptor in the MCF-7 cells might be a charac-
teristic of our cell clone.
Cytotoxicity of GnRH-PAP was tested on the two tumor
cell lines. The GnRH-PAP showed a very signi¢cant cytotox-
icity on the Ishikawa cell line with an ID50 of 15 nM, whereas
the fusion toxin had no e¡ect on MCF-7 cells.
The GnRH moiety di¡ers from the original hormone by the
absence of the pyroglutamic acid residue no. 1. Moreover it is
linked to PAP via a linker (FB). These di¡erences could re-
duce the binding e⁄ciency of the recombinant GnRH to its
receptor, thus a¡ecting the cytotoxicity of the fusion toxin.
When compared to an LH-RH-RNase A conjugate con-
structed by using the chemical cross-linking method (ID50 :
0.5U1036 M) [44], GnRH-PAP ID50 appears very promising.
However, it is lower than the values generally obtained with
recombinant immunotoxins using Pseudomonas exotoxin
(ID50 : 10312 M) [45] or diphteria toxin (ID50 from 1039 M
to 10312 M) [46]. The cytotoxicity is highly dependent on the
targeting moiety and the number of ligand receptors on the
cell surface. The need of a two step PCR ampli¢cation pro-
cedure indicates, in our case, that the GnRH receptors are
poorly expressed in the Ishikawa cells ; this may a¡ect the
cytotoxicity potency. The internalization and the rate of deliv-
ery of the toxin into the cytoplasm are also important factors.
Nevertheless, it is likely that the binding capacity of GnRH-
PAP could be improved by directed mutagenesis which per-
mits the expression of GnRH analogs with greater a⁄nity
than in the case of the original GnRH [24,47]. The absence
of GnRH-PAP cytotoxicity on MCF-7 cells corroborates the
fact that, in these cells, the GnRH receptor was not detected
either by RT-PCR or Western blotting experiments. More-
over, competition between free GnRH and GnRH-PAP on
Ishikawa cells raised the cell viability from 10 to 87%. Hence,
we have a good argument for the speci¢city of the GnRH-
PAP to GnRH receptor positive cell lines.
In recent years, the discovery of speci¢c antigens on tumor
cells has been exploited to develop a new class of therapeutic
agents which associate antibody with a toxin of bacterial or
plant origin (formally known as immunotoxins). At present,
the DNA recombinant gene technology allows the design of
chimeric toxins which associate growth factors or other cell
binding ligands with toxic moieties. Promising results have
been obtained in clinical trials made with the new therapeutic
agents: B cell or T cell malignancies can be treated with im-
munotoxins or chimeric toxins [48]. However, the treatment of
solid tumors with these new therapeutic agents has been dis-
appointing because of poor penetration of tumor mass, result-
ing in a loss of e⁄ciency. Toxic side e¡ects caused by non-
speci¢c cytotoxicity have previously been described [6,49,50].
These results compel researchers to explore new ways for ob-
taining new molecules of improved e⁄ciency, smaller size and
diminished non-speci¢c cytotoxicity.
Very recent experiments have shown that tumor cells bear-
ing GnRH receptors also expressed the ‘death receptor’ Fas
[51]. The ¢xation of GnRH analogues on the GnRH receptors
in these tumor cells induced apoptosis through the expression
of the Fas ligand [52]. In the future, it will be interesting to
investigate if the GnRH-PAP has the ability to induce apop-
tosis in targeted cells and to trigger the expression of Fas/Fas
ligand system. The resulting ampli¢ed apoptosis would im-
prove the e⁄ciency of the GnRH-PAP fusion toxin on solid
tumors.
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